Company: CRNX
Filing Date: 2025-06-26
Form Type: 8-K
Source: 0000950170-25-090405
Chunk: 1

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-06-26
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01 Other Events.

The R& D Day presentation included the following updates on the Company’s pre-clinical development pipeline:

• CRN12755
: The Company provided preclinical data on its lead candidate CRN12755 in the thyroid-stimulating hormone receptor (“ TSHR”) antagonist program for the treatment of Graves’ disease, including the two major manifestations Graves’ hyperthyroidism and Graves’ orbitopathy (Thyroid Eye Disease or “ TED”). CRN12755 was observed to decrease TSAb-stimulated thyroid hormone (T4) in a rat model, and was observed to decrease hyaluronic acid and IL-6 production in Graves Orbital Fibroblasts (GOFs) from TED patients. The Company also provided an overview of the clinical development strategy for CRN12755, including key biomarkers and other data to be captured in the Phase 1 trial.

• CRN10329
: The Company identified CRN10329 as a preclinical leading development candidate for a selective SST3 nonpeptide agonist for the treatment of autosomal dominant polycystic kidney disease (ADPKD). CRN10329 was observed to decrease cystic index, cellular proliferation, kidney weight and aberrant expression of renal tubular injury markers in a mouse model of ADPKD. The Company also shared data highlighting that SST3 is highly and consistently expressed in cyst-lining cells in ADPKD.

• CRN09682:

o

The Company shared data on CRN09682 previously presented at medical conferences. Data show the potency, selectivity and internalization of CRN09682. CRN09682 in tumor and plasma and free MMAE in plasma are not observed after 24 hours in a mouse tumor model, while free MMAE cleaved from CRN09682 persists within the tumor for at least 240 hours. The Company also demonstrated that CRN09682 induced anti-tumor activity in a dose-dependent manner in different mouse tumor growth models without a decrease in body weight.

o

The Company provided additional details regarding the trial design of its Phase 1/2 study, BRAVESST2, of CRN09682 for the treatment of metastatic or locally advanced SST2-positive neuroendocrine tumors and other SST2-expressing solid tumors. In the Phase 1 dose escalation phase, the Company expects to enroll 3-6 patients per cohort until the minimum tolerated dose is confirmed. Data from the dose escalation will inform the recommended